Novartis is conducting two trials comparing Cosentyx, or secukinumab, with AbbVie's Humira and Novartis' own biosimilar. Cosentyx is approved for treating plaque psoriasis, ankylosing spondylitis and psoriatic arthritis.
Trials test Cosentyx against Humira and biosimilar
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.